BI’s Article search uses Boolean search capabilities. If you are not familiar with these principles, here are some quick tips.

To search specifically for more than one word, put the search term in quotation marks. For example, “workers compensation”. This will limit your search to that combination of words.

To search for a combination of terms, use quotations and the & symbol. For example, “hurricane” & “loss”.

Login Register Subscribe

Illumina sued by Columbia University over DNA patents


WILMINGTON, Del. (Reuters)—Illumina Inc, facing a hostile takeover bid by Swiss drugmaker Roche Holding A.G., was sued by Columbia University on Monday for alleged infringement of five patents related to DNA sequencing.

According to the complaint filed in the U.S. District Court in Wilmington, Del., Illumina commercialized its next-generation sequencing products despite knowing about the patents, which were obtained between 2009 and 2012 and assigned to Columbia.

The university said its patents cover NGS technologies that allow rapid and precise DNA sequencing. It said the technologies are particularly important in personalized medicine, in which individuals' genomic DNA sequence information is used as a basis to provide health care.

Illumina makes machines that decode a person's entire genome. Representatives of the company did not immediately respond to requests for comment. A lawyer for Columbia also did not immediately respond to a request for comment.

Columbia's lawsuit seeks royalties, triple damages and other remedies.

The complaint was filed hours after Roche extended its $5.7 billion cash takeover bid for Illumina, which values the San Diego-based company at $44.50 per share. Illumina considers the offer "grossly inadequate."

Acquiring the company would give Roche a leading position in gene sequencing, which could help better identify which patients might benefit from using particular drugs.

Analysts expect Roche to raise its offer. Illumina's shares have traded above $44.50 since the bid became public on Jan. 25. In Monday trading, Illumina shares were down 53 cents at $49.93 on the Nasdaq.

Illumina in 2011 posted profit of $86.6 million on revenue of $1.06 billion. In its annual report, the company projected that expansion in the sequencing market and its product portfolio would drive demand for its technology over the next several years.

Read Next

  • European E.coli outbreak features toxic new strain

    LONDON (Reuters)—A highly infectious new strain of E.coli bacteria is causing a deadly outbreak of food poisoning in Germany, scientists said on Thursday, with cases in Europe and the United States raising the alarm worldwide.